Navigation Links
Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
Date:11/14/2011

tion of heart failure hospitalization events.  Mesoblast expects that these outcomes will be central to the primary endpoint of a Revascor™ Phase 3 trial for product regulatory approval by the United States Food and Drug Administration (FDA).

The randomized, placebo-controlled 60-patient Phase 2 trial compared the safety and efficacy of three doses of Revascor™ on top of maximal approved therapies versus maximal therapies alone in patients with moderate-to-severe congestive heart failure (CHF) defined by New York Heart Association (NYHA) class II or III status and ejection fraction below 40%.  The trial enrolled both ischemic and non-ischemic heart failure patients.  Heart failure patients with this degree of severity are known to have a high cardiac mortality over a 12-24 month period despite being on maximal approved drug and device therapies.

Treatment with MPCs was well-tolerated, with 13% of patients developing transient or persistent anti-donor antibodies which were without clinical consequence. Over a 22-month mean follow-up period, only 1/45 (2%) patients who received a single injection of Revascor™ died of cardiac causes compared with 3/15 (20%) controls (p=0.02).  In addition, MPC treatment significantly delayed the time to a first Major Adverse Cardiac Event, MACE, a composite of cardiac death, heart attack or revascularization procedures (p=0.036), and reduced the overall risk for MACE by 78% (p=0.011).

Over a mean follow-up of 18 months, 0/15 patients who received the highest dose of MPC (150M) had been hospitalized for heart failure or had died.  In contrast, 3/15 (20%) controls and 6/30 (20%) patients who received low (25M) or mid (75M) doses of MPC had either been hospitalized with heart failure or had died. This clinical improvement associated with the 150M dose was accompanied by evidence of cardiac remodelling (reduction in left ventricular end systolic volumes compared with controls
'/>"/>

SOURCE Mesoblast
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
2. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
3. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
4. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
5. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
10. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
11. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 The Competitive Intelligence (CI) ... marketplace changes. CI leaders who adjust will succeed, and ... a new Best Practices, LLC study CI leaders from ... including: - Use secondary research whenever possible ... - Internal staff who are creative thinkers ...
(Date:8/29/2014)... Aug. 29, 2014 Medina Medical announced today ... member of the Board of Directors on August 18, ... development and commercialization experience, including over a decade of ... served as a Partner of the medical device incubator ... of two Foundry start-ups. Mr. Engelson previously served as ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and Markets ... Drug Pipeline Insight 2014" report to their offering. ... US is one of the largest segments of pharmaceuticals industry. ... rate, while the available therapies were unable to meet the ... the market for CNS disorder, especially over the past two ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... 2012 Allscripts (NASDAQ: MDRX) today announced that ... ™ to manage the revenue cycle for 39 affiliated providers ... integrated Allscripts Electronic Health Record (EHR) to automate ... the insights they need to deliver superior patient care. ...
... SAN FRANCISCO, Jan. 4, 2012  Practice Fusion, the ... community in the US, announced today that its ... a faster, simpler and more streamlined user experience ... technology flagged more than 7,000 deadly drug interactions ...
Cached Medicine Technology:Mammoth Hospital Selects Allscripts RCM Services 2Mammoth Hospital Selects Allscripts RCM Services 3Mammoth Hospital Selects Allscripts RCM Services 4Mammoth Hospital Selects Allscripts RCM Services 5Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 2Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 3
(Date:8/29/2014)... The new review that can be read on DailyGossip.org indicates ... will permanently eliminate the symptoms of this disease. , ... cure in as fast as 30 to 60 days. However, ... week. , The Tinnitus Miracle review indicates that this ... loss, pain in the ear and dizziness. Read the full ...
(Date:8/29/2014)... Cosmetic Town is a cosmetic ... plastic surgeons with prospective patients. The site showcases ... techniques in plastic and reconstructive surgery. Articles are ... reliable information for general readers, who are looking ... Town began featuring renowned cosmetic specialists from Los ...
(Date:8/29/2014)... The Nasal Polyps Treatment Miracle ... new program is actually based on some powerful ... by a former nasal polyps sufferer, who in ... problem. Manuel Richards suffered from nasal polyps for ... , Learn more about Manuel Richards' new book ...
(Date:8/29/2014)... The Department of Health and Human ... code CMS–0052–P) today allowing healthcare providers to attest for ... EHR Technology (CEHRT) or a combination of the 2011 ... not been able to fully implement 2014 Edition CEHRT ... continue to use 2011 Edition CEHRT, or a combination ...
(Date:8/29/2014)... Indosoft, Inc., a leading provider of scalable Asterisk-based ... licensing of its Q-Suite 5.7 software. As a ... been successfully deploying and supporting its ACD and Dialer ... the world for more than a decade. The introduction ... option which complements the widespread deployment of Q-Suite in ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:Cosmetic Town Is Now Connecting Patients with Qualified Cosmetic Specialists 2Health News:Nasal Polyps Treatment Miracle Review Exposes New Natural and Permanent Healing Program 2Health News:Quirk Healthcare Outlook on MU2 Delay Confirmation 2Health News:Indosoft Offers Monthly Usage Licensing Terms 2
... of a ban on Coke and Pepsi by the Kerala Government, ... putting forth a proposal to stop the sale// and production of ... ,Top brass in the companies are very unhappy over these ... private company which is not in sync with the reports ...
... Minister Tony Abbott yesterday accused the commonwealth of bankrolling ... public money was spent.// ,He attacked ... should be able to fund public hospitals using the ... ,State health ministers, outraged at Mr Abbott's position accused ...
... too much take-away food and pile on weight will soon ... ,The National Heart Foundation's tick is a label that ... and will soon make its appearance at restaurants, take-away outlets ... by analyst BIS Shrapnel who showed that 70 percent of ...
... for one to undergo an operation.// ,A team ... analysed the outcomes of over 90,000 operations carried out at ... time to have an operation, as they had found that ... published their study in the journal Quality and Safety in ...
... eating raw shellfish have made the U.S. Food and ... raw shellfish. Reports coming// in show that oysters and ... sick across the country. ,Till date there have been ... gastroenteritis after eating raw shellfish. The illness is caused ...
... condition that affects children as well as adults. A ... alleviate// symptoms and bring down the inflammation associated with ... 10 issue of the New England Journal of Medicine. ... the National Institute of Arthritis and Musculoskeletal and Skin ...
Cached Medicine News:Health News:Health Minister Slams State Health Governments 2Health News:Heart Tick for Fast Foods in Australia 2Health News:Surgeries Performed In The Morning Have Less Post-Op Complications 2Health News:NOMID Symptoms Helped By Arthritis Drug 2Health News:NOMID Symptoms Helped By Arthritis Drug 3
... Skin Staple Remover is a plastic ... is packaged 12 units per box ... staples. The device works by slipping ... under the staple to be removed. ...
... place single staples to close surgical ... stainless steel; the staplers are not ... skin staplers to meet your needs., ... for routine skin closure in a ...
... is a full-feature skin stapler with a ... has improved visibility over existing fixed-head skin ... for easier staple placement., ,This Skin ... instrument designed to deliver rectangular, stainless steel ...
... Linear Staplers are available with either a ... instrument (non-reloadable). Each instrument contains 19 staples ... ,Benefits include: , Small profile stapling head ... , Articulating head rotates up to 80deg; ...
Medicine Products: